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The purpose of this research was to investigate mechanisms of antiplatelet action of bioactive principle from S. lycopersicum.
Aqueous fraction had a high content of nucleosides (adenosine, guanosine, and adenosine 5󸀠-monophosphate) by HPLC analysis.
Also aqueous fraction presented flavonoids content. Aqueous fraction inhibited platelet activation by 15 ± 6% (𝑃 < 0.05). Fully
spread of human platelets on collagen in the presence of aqueous fraction was inhibited from 15 ± 1 to 9 ± 1 𝜇m2 (𝑃 < 0.001). After
incubation of whole bloodwith aqueous fraction, the platelet coverage was inhibited by 55± 12% (𝑃 < 0.001). Platelet ATP secretion
and aggregation were significantly inhibited by the aqueous fraction. At the same concentrations that aqueous fraction inhibits
platelet aggregation, levels of sCD40L significantly decreased and the intraplatelet cAMP levels increased. In addition, SQ22536,
an adenylate cyclase inhibitor, attenuated the effect of aqueous fraction toward ADP-induced platelet aggregation and intraplatelet
level of cAMP. Platelet aggregation ex vivo (human study) and thrombosis formation in vivo (murine model) were inhibited by
aqueous fraction. Finally, aqueous fraction may be used as a functional ingredient adding antiplatelet activities (nucleosides and
flavonoids) to processed foods.
1. Introduction
Cardiovascular diseases (CVD) currently accounts for nearly
half of noncommunicable diseases, accounting for 17.3 mil-
lion deaths per year, a number that is expected to grow
to >23.6 million by 2030 [1]. The platelet activation and
subsequent platelet aggregation play an essential role in the
development and progression of CVD [2, 3]. Thus, after
platelets get activated and form aggregates, they increase
the secretion of other potentially pro-atherogenic molecules,
such as IL-1𝛽, sCD40L, CCL5 and sP-selectin [4, 5]. Of this
form, platelets are not only key mediators of thrombosis
but also in inflammation by directly interactacting with
leukocytes and others cell [6–8]. P-selectin and sCD40L
platelet-derived seems to contribute to atherosclerotic lesion
development and arterial thrombogenesis by forming large
stable platelet-leukocyte aggregates [9, 10].
Interestingly, data from experimental, epidemiological
and clinical studies indicates that fruit and vegetable (F&V)
consumption have profound cardio-protective effects in the
primary as well as secondary prevention of coronary heart
disease, hence they are considered as cardiovascular friendly
natural products [11]. Presently, in addition to their recog-
nized high value in vitamins, minerals and dietary fiber,
consuming F&V is associated with phytochemical content
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[12, 13], with specific actions on target functions [14]. In this
sense, studies have demonstrated the platelet antiaggregant
activity of fruits (red grapes, strawberries, kiwis and pineap-
ples) and vegetables (garlic, onions, green onions, melons
and tomatoes) [15, 16]. Among these elements of a healthy
diet, consumption of tomato (Solanum lycopersicum) has
been suggested to play an important role in preventing
cardiovascular problems given to the phytochemicals with
antioxidant activities [17–19].
However, very little is known on the mechanisms invo-
lved in the antiplatelet effects of S. lycopersicum and its bio-
active compounds. The main aim of this work was to investi-
gate mechanisms of antiplatelet and antithrombotic activities
of aqueous fraction from S. lycopersicum and bioactive
compounds that provide this activity.
2. Materials and Methods
2.1. Reagents. The agonists adenosine 5󸀠-diphosphate bis
(ADP), thrombin receptor-activating peptide 6 (TRAP-6),
and arachidonic acid were from Sigma-Aldrich (St. Louis/
MO, USA), while the collagen was obtained from Hormon-
Chemie (Munich, Germany). Calcein-AM, bovine serum
albumin (BSA), SQ22536 (adenylate cyclase inhibitor) aden-
osine, guanosine, adenosine 5󸀠-monophosphate (AMP), gal-
lic acid, quercetin, aluminium chloride (AlCl
3
), and Folin-
Ciocalteu reagent were obtained Sigma-Aldrich (St. Louis/
MO, USA), whereas luciferase/luciferin reagent was obtained
from Chrono-Log Corp (Havertown, PA), and microfluidic
chambers were from Bioflux (Fluxion, San Francisco, CA,
USA). Annexin V FITC Apoptosis Kit was obtained from BD
Pharmingen (BD Biosciences, San Diego, CA, USA).
2.2. Bioactive Extract and Fraction. Total extract and aqueous
fraction from Solanum lycopersicumwere obtained according
to Fuentes et al. [20]. Briefly, the total extract was fractionated
by liquid-liquid separation, obtaining an aqueous, ethyl
acetate, and petroleum ether fractions. The aqueous fraction
was lyophilized (Labconco, Freezone 6, Kansas City, MO,
USA) and stored at −70∘C until use.
2.3. Total Phenolic and Total Flavonoid Content. Determina-
tion of total phenolic contents was determined using Folin–
Ciocalteu reagent as adapted from Velioglu et al. [21], with
slight modifications. In brief, 20 𝜇L of extract or fraction
was mixed with 100𝜇L of Folin-Ciocalteu reagent previously
diluted with 1.58mL of distilled water and allowed to stand
at room temperature for 8min; 300 𝜇L of sodium carbonate
(20%) solution was added to the mixture. After 120min at
room temperature, absorbancewasmeasured at 725 nmusing
a Unicam Helios Gamma spectrometer (Thermo Spectronic,
Helios Gamma, Cambridge, UK) within the range of linearity
(0.05–0.8mM). Results were expressed as mg gallic acid
equivalents in 100 g of the dried extract (mg GAE/100 g).
The total flavonoid content of the extract or fraction was
determined as follows [22]. Briefly, to 0.1mL of sample,
2.35mL methanol and 50𝜇L of 5% AlCl
3
ethanolic solution
were added. After 1 h at room temperature, the absorbance
was measured at 415 nm. Quercetin was used as a reference
for the calibration curve, and results were expressed as mg
quercetin equivalents per 100 g dried extract (mg QE/100 g).
Total phenolic and total flavonoid contents were reported as
mean ± SEM for at least three replications.
2.4. HPLC Analysis. Analysis of the chemical profile of
bioactive compound of aqueous fraction from S. lycopersicum
was performed by HPLC Merck-Hitachi (La-Chrom, Tokyo,
Japan) equipment consisting of an L-7100 pump, an L-7455
UV diode array detector, and a D-7000 chromatointegrator.
HPLC-DAD analysis was carried out using a 250mm ×
4.60mm i.d. and 5 𝜇m C18-RP Luna column (Phenomenex,
Torrance, CA, USA) maintained at 25∘C with a linear gra-
dient solvent system consisting of 1% formic acid (A) and
acetonitrile (B) as follows: 95–90% A over 10min, 90–50%
A over 10min, 50–0% A over 5min, and followed by 0–95%
A from 25 to 30min at a flow rate of 1mL/min. UV spectra
from200 to 600 nmwere recorded for peaks characterization.
Standards of guanosine, AMP, and adenosine were used for
HPLC-DAD identification and determination and dissolved
in acetonitrile-formic acid (99 : 1, v/v) to prepare standard
solutions ranging from 0.125 to 1mg/mL. Aqueous fraction
was lyophilized and then equilibrated to room temperature
for 1 h and dissolved in acetonitrile-formic acid (99 : 1, v/v).
All samples were filtered through a 5 𝜇m filter (Millipore
Corporation, Bedford,MA), and then 20𝜇Lwere injected.All
samples were run in triplicate.
2.5. Preparation of Human Platelet Suspensions. Venous
blood samples were obtained from two healthy volunteers not
taking aspirin or other nonsteroidal anti-inflammatory drugs
for at least 10 day, in 3.2% citrate tubes (9 : 1 v/v) by
phlebotomy with vacuum tube system (Becton Dickinson
Vacutainer Systems, Franklin Lakes, NJ, USA). The proto-
col was approved by the Institutional Review Board Talca
University in accordance with the Declaration of Helsinki.
Informed consent was signed before the blood was drawn.
The samples were gently mixed by 5-fold inversion and
allowed to stand for 5minutes. The tubes were centrifuged
(DCS-16 Centrifugal Presvac RV) at 240 g for 10minutes
to obtain platelet-rich plasma (PRP). Platelet count in PRP
was performed in a hematologic counter (Bayer Advia 60
Hematology System, Tarrytown, NY, USA). The original
tubes were centrifuged at 650 g for 10 minutes to obtain the
platelet-poor plasma (PPP). Finally, the PRP was adjusted
to 200 × 109 platelets/L with PPP. Washed platelets were
prepared by adding 50 ng/mL PGE
1
to the PRP, and platelets
were then pelleted at 750 g for 10 minutes. Platelets were
washed once in Tyrode-Hepes buffer containing 50 ng/mL
PGE
1
and 1mmol/L EDTA, pH 7.4, and resuspended in
Tyrode-Hepes to a concentration of 250 × 109/L. Given the
use of vacutainers for different experiments, samples were
examined to discard the presence of platelet preactivation
before isolation of PRP/washed platelets, by normal platelet
count and absence of clots.
2.6. FlowCytometry. Loss of plateletmembrane phospholipid
asymmetry with externalization of phosphatidylserine was
assessed by the binding of annexin V by flow cytometry.
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To 480 𝜇L of citrated whole blood, collagen 1.5 𝜇g/mL and
ADP8 𝜇mol/L (final concentrations)were added for 10min at
37∘C, with stirring at 1.000 rpm. In each experiment, previous
to the addition of platelet agonists, PRP was incubated with
saline or aqueous fraction (1mg/mL) for 10min at room
temperature. Briefly, 50𝜇L of PRP was diluted with 150𝜇L
of binding buffer (10mmol/L Hepes, 150mmol/L NaCl,
5.0mmol/L KCl, 1.0mmol/L MgCl
2
, 2.0mmol/L CaCl
2
, pH
7.4) and incubated for 25min in the dark with 0.6 𝜇g/mL
(final concentration) of annexin V-FITC (Sigma Chemical,
St. Louis, MO) and anti-CD61-PE, (Pharmingen, San Diego,
CA). The samples were acquired and analyzed in Accuri C6
flow cytometer (BD, Biosciences, USA). Platelet populations
were gated on cell size using forward scatter (FSC) versus
side scatter (SSC) and CD61 positivity to distinguish it from
electronic noise. The light scatter and fluorescence channels
were set at logarithmic gain, and 5000 events per sample were
analyzed. Fluorescence intensities of differentially stained
populations were expressed as mean channel value using the
CSampler Software (BD Biosciences, USA).
2.7. Measurement of Platelet Aggregation and Secretion. Pla-
telet aggregationwasmonitored by light transmission accord-
ing to Born and Cross [23], using a lumi-aggregometer.
Briefly, 480 𝜇L of PRP in the reaction vessel was preincubated
with 20𝜇L of saline, total extract (1mg/mL), or aqueous
fraction (1mg/mL). After 3 min of incubation, 20 𝜇L of
agonist was added to initiate platelet aggregation, which
was measured for 6min. ADP 8𝜇mol/L, collagen 1.5 𝜇g/mL,
TRAP-6 30 𝜇mol/L, and arachidonic acid 1mmol/Lwere used
as agonists. All measurements were performed in triplicate.
The results of platelet aggregation (maximal amplitude [%],
slope, area under the curve, and lag time [s]) were determined
by the software AGGRO/LINK (Chrono-Log, Havertown,
PA, USA).The inhibition of the maximal platelet aggregation
by the fraction was expressed as a percentage with respect to
control (saline).
Platelet secretion was determined by measuring the
release of ATP using luciferin/luciferase reagent. Luciferin/
luciferase (50𝜇L) was added to 480 𝜇L of platelet suspension
(PRP adjusted to 200 × 109 platelets/L) within 2min before
stimulation. Platelet secretion was recorded in real time in
a lumi-aggregometer (Chrono-Log, Havertown, PA, USA) at
37∘C with stirring (1.000 rpm). To examine the effects on
platelet secretion, platelets were preincubated with saline or
aqueous fraction (1mg/mL) for 3min prior to the addition of
ADP 8𝜇mol/L [24].
2.8. Platelet Spreading Assay. Coverslips were coated with
collagen (100𝜇g/mL) and incubated at 37∘C, for 60 minutes.
Then they were rinsed with phosphate buffered saline (PBS),
blocked with BSA 1% for 60 minutes at 37∘C and finally
washed with PBS to remove any unbound BSA. Washed
platelets (5 × 109 platelets/L) were labeled with calcein-AM
(4 𝜇mol/L), preincubated with aqueous fraction (1mg/mL)
or apyrase (2 units/mL) for 1 hour at room temperature
and then allowed to spread on collagen for 1 hour at 37∘C
[25]. After gently rinsing 3 times with PBS, spread platelets
were mounted in Vectashield mounting medium (Vector
Laboratories, Burlingame, CA). The images were acquired
with Zeiss 40x oil-immersion lens (1.3 numeric aperture)
and Photometrics SenSys camera (Photometrics, Tucson,
AZ) from 4 consecutive fields and examined using a Carl
Zeiss LSM700 confocalmicroscope (Carl Zeiss, Oberkochen,
Germany) and the argon-krypton laser at 488 nm to generate
the fluorescent calcein signal detected between 490 nm and
530 nm. The images were analyzed using Image J software
(version 1.26t, NIH, USA).
2.9. Platelet Adhesion and Aggregation under Controlled Flow.
Experiments under flow were performed in a BioFlux 200
flow system (Fluxion, San Francisco, CA, USA) with high
shear plates (48 wells, 0–20 dyne/cm2). Using manual mode
in the BioFlux software, the microfluidic chambers were
coated for 1 hour with 20𝜇L of collagen 200𝜇g/mL at a wall
shear rate of 200 s−1.
The plaque coating was allowed to dry at room tempera-
ture for one hour. The channels were perfused with PBS for
10min at room temperature at wall shear rate of 200 s−1 to
remove the interface. Then, the channels were blocked with
BSA 5% for 10 min at room temperature at wall shear rate
of 200 s−1. Whole blood anticoagulated with sodium citrate
was labeled with calcein-AM (4𝜇mol/L) and incubated at RT
with saline or aqueous fraction (1mg/mL). After one hour
of incubation, the blood was added to the inlet of the well,
and chambers were perfused for 10min at room temperature
at a wall shear rate of 1000 s−1. The plates were mounted
on the stage of an inverted fluorescence microscope (TE200,
NIKON, Japan) [26].
Platelet deposition was observed and recorded in real
time (30 frames per min) with a CCD camera (QICAM,
QIMaging, Surrey, BC, Canada). We used bright field and
fluorescencemicroscopy for real-time visualization of platelet
adhesion and aggregation in flowing blood. For each flow
experiment, fluorescence images were analyzed off-stage by
quantifying the area covered by platelets with the Image J
software (version 1.26t, NIH, USA). In each field, the area
covered by platelets was quantified.
2.10. Measurement of cAMP Levels in Platelets. The effect of
aqueous fraction on platelet levels of cAMP was evaluated in
PRP samples (500𝜇L) following 5 min incubation without
stirring. Platelet reactions were stopped with 150 𝜇L of ice-
cold 10% trichloroacetic acid. Precipitated proteins were
removed by centrifugation at 2.000 g for 15min at 4∘C. Fol-
lowing addition of 150 𝜇L ofHCl 1mol/L, the supernatant was
submitted to 6 ether extractions v/v and lyophilized. Samples
were stored at −70∘C until assay. Before determination, the
powder was dissolved in 200𝜇L of PBS, pH 6.2. cAMPDirect
Immunoassay Kit (BioVision Research Products, Mountain
View, CA, USA) was employed.
2.11. Effect of SQ22536 on ADP-Induced Platelet Aggregation
and Intraplatelet Level of cAMP. To elucidate whether anti-
platelet effect of aqueous fraction was mediated by stim-
ulation of cAMP production, PRP was pretreated with
SQ22536 (250 and 500𝜇mol/L) for 3min and followed by the
addition of aqueous fraction (1mg/mL). Platelet aggregation
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Figure 1: Bioactive compounds indentified in aqueous fraction from S. lycopersicum by HPLC.
was measured by addition of ADP 8 𝜇mol/L. Platelets pre-
treated with SQ22536 (250 and 500 𝜇mol/L) and followed by
the addition of aqueous fraction (1mg/mL) were prepared
for measurement of intraplatelet level of cAMP as described
above.
2.12. Measurement of sCD40L Levels. Soluble CD40 ligand
(sCD40L) was determined using a Human sCD40-Ligand
Quantikine kit (R&D systems, Minneapolis, MN). Briefly,
washed platelet was pretreated with saline, aqueous fraction
(1mg/mL), or aspirin 0.3mmol/L for 15min at 37∘C and then
stimulated by thrombin (2U/mL) for 45 at 37∘C. Finally,
the supernatants were collected following centrifugation at
11.000 g for 10min at 4∘Cand stored at−70∘Cprior to sCD40L
measurements by ELISA as described earlier [27].
2.13. Thrombus Formation in Murine Model. This model is
an adaptation of one previously described [28]. Briefly, mice
(12–16 weeks old) were anesthetized with a combination of
tribromoethanol (270mg/kg) and xylazine (13mg/kg). The
mesentery was exposed by central incision in the abdomen,
permitting visualization of thrombus development inmesen-
teric artery. The mice were injected with rose bengal (Sigma,
St Louis, MO) through tail vein injection in a volume of
0.1mL at a concentration of 50mg/kg. Just after injection, a
1.5-mW green light laser (532 nm) was applied to the desired
site of mesenteric artery, and blood flow was monitored for
60 minutes. Stable occlusion was defined as a blood flow
of 0mL/min for 3 minutes. Control group (saline, 𝑛 = 5),
acetylsalicylic acid (200mg/Kg, 𝑛 = 5), or aqueous fraction
(200mg/kg, n= 5) was administered intraperitoneally 30min
before experiment.
2.14. Measurement of Platelet Aggregation Ex Vivo. Six appar-
ently healthy volunteers (3 men and 3 women; age 23 to
30 years), with no history of haemostatic disorders, were
instructed to abstain from consuming drugs known to affect
platelet function for a 10-day period before their participation
in the study. Written informed consent was obtained from all
subjects. The study was approved by the Institutional Review
Board Talca University. Platelet aggregation induced by ADP
(4 𝜇mol/L) was studied before (baseline) and four hours after
oral administration of tomato aqueous fraction (70mg/kg)
diluted in 50mL of orange juice.
2.15. Statistical Analysis. All data are expressed as mean ±
standard error of mean (SEM). Differences between the dif-
ferent groups were analysed by Student’s paired or unpaired
t-test and one-way analysis of variance with Duncan’s post-
hoc test using SPSS version 17.0. The statistical significance
level was set up at 𝑃 < 0.05.
3. Results
3.1. Total Phenolic and Total Flavonoid Contents. The total
phenols presented statistically significant differences and
were in the following order: aqueous extract (11 ± 1mg
GAE/100 g) > aqueous fraction (6.8 ± 0.9mg GAE/100 g)
(𝑃 < 0.05), and the total flavonoids presented the similar
order, but no significant differences: aqueous extract (1.74 ±
0.3mgQE/100 g) > aqueous fraction (1.52 ± 0.5mgQE/100 g)
(𝑃 > 0.05).
3.2. Chromatographic Analysis of S. lycopersicum Aqueous
Fraction. HPLC analysis of aqueous fraction from S. lycop-
ersicum revealed a group of nucleosides, which have been
known as adenosine, guanosine, and AMP (Figure 1). Based
on HPLC determination, the content of nucleosides in aque-
ous fraction was in the following increasing order: guanosine
(5.4mg/g dried), AMP (9.9mg/g dried), and adenosine
(155mg/g dried). Similar compounds have been reported by
1H-NMR using total tomato extract of the same plant [29].
3.3. Total Tomato Extract Inhibits Platelet Aggregation Induced
by Different Agonists. To first explore the potential anti-
platelet activity of S. lycopersicum, a total extract was tested
on platelet aggregation induced by different agonists. The
effect of total extract from fully mature tomatoes on platelet
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Figure 2: Effects of total extract on platelet aggregation. (a) PRP was incubated with saline or total extract (1mg/mL) as indicated for 3min,
prior to measuring human platelet aggregation induced by ADP 8𝜇M, collagen 1.5 𝜇g/mL, AA (arachidonic acid 1mM) or TRAP-6 30 𝜇M,
and (b) PRP was incubated with saline or total extract (1mg/mL) for 20, 60, and 180 seconds, prior to measuring human platelet aggregation
induced by ADP 8 𝜇M.The graph depicts the mean ± SEM of 𝑛 = 3 experiments. ∗𝑃 < 0.05. PRP: platelet-rich plasma.
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aggregation induced by ADP, collagen, TRAP-6, and arachi-
donic acid is shown in Figure 2. The total extract (1mg/mL)
inhibited ADP- and collagen-induced platelet aggregation by
36 ± 10% and 19 ± 4%, respectively (𝑃 < 0.05 versus control)
(Figure 2(a)).The time dependency of this effect was tested by
preincubation of PRP with the extract at different times (20,
60, and 180 seconds) before the addition of ADP 8𝜇mol/L. As
observed in Figure 2(b) the inhibitory activity was significant
even after 20 seconds of incubation with an average of 34 ±
8% as compared to that the control.
3.4. Aqueous Fraction of S. lycopersicum Inhibits Several
Platelet Activation Events. We investigated the antiplatelet
effects of the aqueous fraction of S. lycopersicum obtained
by liquid-liquid separation by testing its activity on different
activation-dependent events in human platelets. Activated
platelets expose phosphatidylserine (PS), which is a key
phenomenon for generating a burst of thrombin essen-
tial to thrombus growth. The aqueous fraction inhibited
collagen/ADP-induced externalization of PS assessed by
annexin V binding by 15 ± 6% (𝑃 < 0.05) (Figure 3). It
is well established that platelets undergo a dramatic change
in morphology upon binding to immobilized adhesive pro-
teins [30]. To expand the understanding of the effects of
aqueous fraction as an inhibitor of collagen-mediated inside-
out signaling, we assessed its effect on platelet spreading
on collagen-coated surfaces. The fully spreading of human
platelets on immobilized collagen in the presence of aqueous
fraction was inhibited from 15 ± 1 to 9 ± 1𝜇m2 (𝑃 <
0.001) (Figure 4). ADP-induced platelet aggregation andATP
release were inhibited by 54 ± 13% and 52 ± 5%, respectively
(𝑃 < 0.05) (Figure 5).
3.5. Aqueous Fraction of S. lycopersicum Impairs Platelet Adhe-
sion on Immobilized Collagen under Flow Conditions. The
effects of aqueous fraction on platelet adhesion/aggregation
to immobilized collagen under arterial flow conditions are
shown in Figure 6. After perfusion of citrate-anticoagulated
blood over collagen-coated plaque surfaces at 37∘C with a
wall shear rate of 1000 s−1 for 10 min, rapid platelet adhesion
and aggregate formationwere observed (Figure 6 and supple-
mental video 1). Aqueous fraction reduced collagen-induced
platelet adhesion and aggregate formation under controlled
flow. After aqueous fraction incubation of blood, the platelet
coverage was inhibited by 55 ± 12% (𝑃 < 0.001) (Figure 6 and
supplemental video 2).
3.6. Effect of Aqueous Fraction of S. lycopersicum on Intra-
platelet Levels of cAMP. Because we have recently demo-
nstrated that the aqueous fraction from S. lycopersicum
contains significant amounts of adenosine [20], we hypoth-
esized that the antiplatelet effect could be exerted by rising
cAMP levels. At 1mg/mL the aqueous fraction significantly
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Figure 5: Aqueous fraction inhibited platelet aggregation and ATP secretion. (a) saline and (b) aqueous fraction (1mg/mL). Luciferin/
luciferase reagent and then ADP 8 𝜇M were added to PRP to induce aggregation and secretion, which were recorded in real time using
the lumi-aggregometer. Each aggregation curve is representative of multiple traces obtained from three separate platelet donors. The graph
depicts the mean ± SEM of 𝑛 = 3 experiments. ∗∗𝑃 < 0.01. PRP: platelet-rich plasma.
increased the intraplatelet levels of cAMP from 3.5 ± 1 to 20
± 2 pmol/108 platelets (𝑃 < 0.05).
3.7. Effect of SQ22536 on ADP-Induced Platelet Aggregation
and Intraplatelet Level of cAMP. cAMP production through
adenylate cyclase activation has been shown to inhibit platelet
aggregation [31]. Interestingly we found that SQ22536 atten-
uated the increase of intraplatelet levels of cAMP by aqueous
fraction from 20 ± 2 to 5 ± 2 and 3 ± 1 pmol/108 platelets
at concentrations of 250 and 500𝜇mol/L, respectively (𝑃 <
0.05).
We therefore tested whether SQ22536 could reverse
the inhibitory effect of aqueous fraction (1mg/mL) toward
ADP-induced platelet aggregation. Of this forma, SQ22536
was able to reverse the inhibition of aqueous fraction
(1mg/mL) on ADP-induced platelet aggregation. Thus,
SQ22536 attenuated the inhibitory effect of aqueous fraction
toward ADP-induced platelet aggregation by 34 and 52% at
concentrations of 250 and 500 𝜇mol/L, respectively (𝑃 <
0.001) (Figure 7). As a control, SQ22536 by itself did not show
effect on ADP- (8𝜇mol/L) induced platelet (Figure 7).
3.8. Effect on Levels of sCD40L. Asplatelets are considered the
major source of sCD40L in the blood [32], we examined the
effect of aqueous fraction on release of sCD40L. As observed
in Figure 8, we found that aqueous fraction significantly
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Figure 6: Effect of aqueous fraction on collagen-induced platelet adhesion and aggregation under arterial flow conditions. Citrate-
anticoagulated blood was preincubated with saline or aqueous fraction (1mg/mL) for 1 hour and then was perfused over plaque-coated
surfaces for 10min at room temperature at a shear rate of 1000 s−1. (a) Time lapse of 10min at 1000 s−1, at 30 sec intervals, representative flow
images at 40x, (b) the intensity (CTCF) over a time lapse, and (c) bar diagram (values are mean ± SEM; 𝑛 = 3). ∗∗∗𝑃 < 0.001.
reduced thrombin-induced sCD40L release from platelets
(𝑃 < 0.001). Even aqueous fraction had a similar effect that
aspirin.
3.9. Effect on Arterial Thrombus Formation In Vivo. All
animals in this study showed similar physiological values
for rectal temperature before and after thrombosis model
among groups (data not shown). To study arterial thrombus
development in mesenteric artery, anesthetized animals were
administered with saline, acetylsalicylic acid, or aqueous
fraction at a dose of 200mg/kg body weight by intraperi-
toneal injection. We examined the effect of aqueous fraction
on arterial thrombus formation, as shown in Figure 9. The
arterial thrombosis formation to 60min was inhibited from
98 ± 2 to 30 ± 1% (𝑛 = 5, 𝑃 < 0.001) occlusion by pretre-
atment with antiplatelet agents such as acetylsalicylic acid.
During the time in which blood flowwasmonitored, aqueous
fraction significantly inhibited arterial occlusion. Adminis-
tration of aqueous fraction (occlusion: 78± 1%, 𝑛 = 5) showed
significant reductions in occlusion size compared with the
negative control to 60 min (occlusion: 98 ± 2%, 𝑛 = 5)
(𝑃 < 0.05). Over time, both acetylsalicylic acid and aqueous
fraction present a similar kinetics of inhibition of arterial
thrombosis formation (Figure 9(b)).
3.10. Acute Administration of Aqueous Tomato Fraction
Inhibits ADP-Induced Platelet Aggregation inHealthy Subjects.
Platelet aggregation induced by ADP was significantly redu-
ced as compared with baseline values after intake of aqueous
tomato fraction by healthy human subjects. The average
baseline platelet aggregation for thewhole groupwas 86± 7%.
In 6 healthy subjects who received the aqueous fraction, four
hours after treatment we observed a significant inhibition of
platelet aggregation induced by ADP for 19 ± 7% compared
with respect to basal (𝑃 < 0.05) (Figure 10). The volunteers
after treatment did not reporte side effects, such as dizziness,
stomach pain, and fever.
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4. Discussion
In this study, we have demonstrated that aqueous fraction
of S. lycopersicum displayed a range of antiplatelet activities
targeting different platelet activation responses in vitro, ex
vivo and in vivo. This activity is mainly due to the presence of
bioactive compounds (nucleosides and flavonoids) identified
in aqueous fraction with antiplatelet activity [33–35].
Given the central role played by platelets in the pathogen-
esis of atherothrombosis, a variety of antiplatelet agents have
been developed to prevent thrombotic ischemic events [36].
Although antiplatelet drugs have being used widely in the
management of acute episodes and secondary prevention, its
effectiveness in primary prevention is still a matter of debate,
and CVDs still represent the leading causes of morbidity and
mortality, worldwide [37]. In this sense, a dietary strategy
for the prevention of cardiovascular diseases appears to be
demanding and highly relevant in preventive medicine [37].
In fact, epidemiological studies have provided evidence of a
protective role of healthy diets in the prevention of cardiovas-
cular diseases [38].The protective effects of F&Vmay be orig-
inated from several phytochemicals present in foods.We have
recently demonstrated that S. lycopersicum exerts antiplatelet
activity through the inhibition of platelet aggregation induced
by ADP and collagen [39, 40]. In the same line, we found
that total extract of S. lycopersicumwas thermally stable in the
temperature range of 20 to 100∘C, and both acid and alkali did
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Figure 9: Aqueous fraction inhibited arterial thrombosis formation. (a) Representative images of thrombus formation after laser-injured
vascular injury in mouse mesenteric artery, saline control group (𝑛 = 5), ASA (acetylsalicylic acid) (200mg/Kg, 𝑛 = 5), and aqueous fraction
(200mg/Kg, 𝑛 = 5) to 60min and (b) representative time course changes of thrombus growth rate.
not affect inhibition of platelet aggregation induced by ADP
[41]. In the present study, we extended these observations
exploring the antiplatelet effects of an aqueous fraction of S.
lycopersicum.
The mechanisms involved in the inhibition of platelet
aggregation by aqueous fraction from S. lycopersicum have
not been yet elucidated. In the present study, the aqueous
fraction inhibited platelet activation induced by collagen and
ADP. When platelets adhere to collagen, a ligand-binding-
induced signal is generated, leading to platelet spreading that
render adherent platelets resistant to the shear forces at the
site of vascular damage. To study whether S. lycopersicum
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Figure 10: Administration of aqueous fraction inhibiting ADP-
induced platelet aggregation in healthy subjects. Platelet aggregation
in PRP induced by ADP 4𝜇M was studied before (basal) and four
hours after oral administration of aqueous fraction (70mg/kg). The
graph depicts the mean ± SEM of 𝑛 = 6 (each in triplicate) healthy
volunteers. ∗𝑃 < 0.05. PRP: platelet-rich plasma.
fraction was able to inhibit spreading, platelets were allowed
to adhere to collagen, and spreading was evaluated by
differential interference contrast and confocal microscopy.
As shown in Figure 4 aqueous fraction prevented platelet
spreading onto collagen under static conditions.
Under conditions of arterial shear, platelets tethered to
immobilized collagen. Aqueous fraction significantly redu-
ced platelet adhesion and aggregation to collagen as com-
pared with that in the negative control. In addition,
we found that the same doses of aqueous fraction that
caused a significant inhibition of platelet secretion and
aggregation also produced a substantial increase in platelet
cAMP levels. In this study SQ22536, an adenylate cyclase
inhibitor, at different concentrations was able to attenuate
the platelet antiaggregant activity and increase of cAMP
by aqueous fraction. The inhibition of platelet aggregation
by aqueous fraction is thought to be mediated by the
stimulation of adenylate cyclase with increase of intraplatelet
cAMP concentrations. Thus, this study provides the first
documentation that aqueous fractions from S. lycopersicum
have the ability to markedly raise human platelet cAMP
levels, which contradicts previous results of Lazarus and
Garg [35]. The anterior can be explained by the presence of
nucleosides and flavonoids in aqueous fraction. Nucleosides
and flavonoids act on adenylate cyclase participation with
increase of cAMP levels (antiplatelet activity) [42, 43]. Also
O’Kennedy established that tomato extracts inhibit platelet
P-selectin expression after being stimulated by ADP [34].
Thus the relationship between cAMP levels and P-selectin
expression is because cAMP via activation of PKA is capable
of inhibiting platelet P-selectin expression [44, 45]. However,
also it is possible that flavonoids present in the aqueous
fraction can inhibit platelet function by another mechanism
of action.
Moreover, studies establish that the inhibitory effect of
adenosine or fraction from tomato rich in adenosine on
platelet aggregation disappears after the addition of adeno-
sine-deaminase [33, 46]. However, inosine (naturally occu-
rring nucleoside degraded from adenosine) possesses
antiplatelet activity in vitro and in vivo [47].
Reports in the last decade have described that the
secretion of proinflammatory molecules (sCD40L, RANTES,
sP-selectin, etc.) by platelet exacerbates the inflammatory
response and generates a transition to an unstable plaque
[7]. Thus, high levels of sCD40L have been associated with
platelet activation, suggesting a prognostic value in patients
with advanced atherosclerosis [48]. The present study indi-
cates that aqueous fraction not only inhibits platelet function,
but also decreases the inflammatory component of activated
platelets, through a lower release of sCD40L.
Inhibition of platelet aggregation by drugs may repre-
sent an increased therapeutic possibility for such diseases.
Platelet aggregation plays a pathophysiological role in arterial
thrombosis [49]. Because the antiplatelet activity of aqueous
fraction, it was studied on thrombus formation using a
murine arterial thrombus formation in vivo, which causes
formation of a mixed platelet/fibrin thrombus [50]. In the
arterial thrombosismodel, aqueous fraction inhibited arterial
thrombus growth presenting similar kinetics of inhibition
that aspirin, a classical reference drug.
The consumption of aqueous fraction components led
to a reduction of 20% from baseline platelet aggregation
response in the human study. The solution administered
contained 4.9 g of aqueous fraction (e.g., for 70Kg of body-
weight), which is equivalent to the quantity of aqueous
fraction found in 6 fresh tomatoes. This amount of fresh
tomatoes, which contains the active fraction required to
reduce platelet function, is similar to that reported by
O’Kennedy et al. [34].
In the present study, besides the known platelet antiaggre-
gant activity, we demonstrated that the aqueous fraction from
S. lycopersicum strongly inhibited platelet activation events.
The broad range of antiplatelet effects found in the aqueous
fractions of S. lycopersicum may render this functionally
active principle in potents inhibitors of platelet function
(nucleosides andflavonoids)with a potential preventive effect
on thrombus formation.
5. Conclusion
The mechanisms underlying the antiplatelet action of aque-
ous fraction from S. lycopersicum seem to be related to the
inhibition of platelet function through a substantial increase
of intraplatelet levels of cAMP with significative effect
on atheroinflammation/atherothrombosis. These effects, in
terms of primary prevention, could modify cardiovascular
risk without any of the side effects normally associated with
antiplatelet drugs. Moreover, S. lycopersicum may constitute
a functional ingredient adding antiplatelet activities to pro-
cessed foods.
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